|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation expense | |||||
| Stock-based compensation expense | |||||
| Net accretion of discounts on marketable securities | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Unbilled accounts receivable | |||||
| Prepaid expenses and other current assets | |||||
| Operating lease assets and liabilities | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Deferred revenue | |||||
| Net cash used in operating activities | |||||
| Investing activities | |||||
| Purchases of marketable securities | |||||
| Maturities of marketable securities | |||||
| Purchases of property and equipment | |||||
| Net cash provided by investing activities | |||||
| Financing activities | |||||
| Proceeds from initial public offering of common stock, net of underwriting discounts and commissions | |||||
| Proceeds from issuance of common stock and pre-funded warrants in connection with public offerings, net of issuance costs | |||||
| Proceeds from issuance of common stock under benefit plans, net | |||||
| Net cash provided by financing activities | |||||
| Net increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | |||||
| Cash, cash equivalents, and restricted cash, end of period | |||||
| Supplemental cash flow information | |||||
| Cash paid for operating lease liabilities | |||||
| Non-cash investing and financing activities: | |||||
| Offering costs unpaid at end of period | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...